{"id":"ajmaline","rwe":[],"tags":[{"label":"ajmaline","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Potassium voltage-gated channel subfamily A member 5","category":"target"},{"label":"KCNA5","category":"gene"},{"label":"KCND3","category":"gene"},{"label":"CYP2D6","category":"gene"},{"label":"C01BA05","category":"atc"},{"label":"Active","category":"status"},{"label":"Cardiac arrhythmia","category":"indication"},{"label":"Supraventricular arrhythmia","category":"indication"},{"label":"Ventricular arrhythmia","category":"indication"},{"label":"Anti-Arrhythmia Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Sodium Channel Blockers","category":"pharmacology"},{"label":"Voltage-Gated Sodium Channel Blockers","category":"pharmacology"}],"phase":"phase_3","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"ajmalin","offLabel":[],"synonyms":["ajmaline hydrochloride","ajmaline HCl","aritmina","rauverid","ajmaline","(+)-Ajmaline","ajmalin","cardiorythmine","gilurytmal","raugalline"],"timeline":[],"brandName":"Ajmalin","ecosystem":[{"indication":"Cardiac arrhythmia","otherDrugs":[],"globalPrevalence":null},{"indication":"Supraventricular arrhythmia","otherDrugs":[],"globalPrevalence":null},{"indication":"Ventricular arrhythmia","otherDrugs":[{"name":"bretylium","slug":"bretylium","company":"Intl Medication"},{"name":"disopyramide","slug":"disopyramide","company":"Gd Searle Llc"},{"name":"lidocaine","slug":"lidocaine","company":"Fresenius Kabi Usa"},{"name":"mexiletine","slug":"mexiletine","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Potassium voltage-gated channel subfamily A member 5","targets":[{"gene":"KCNA5","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily A member 5","protein":"Potassium voltage-gated channel subfamily A member 5"},{"gene":"KCND3","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily D member 3","protein":"Potassium voltage-gated channel subfamily D member 3"},{"gene":"CYP2D6","source":"DrugCentral","target":"Cytochrome P450 2D6","protein":"Cytochrome P450 2D6"},{"gene":"SCN5A","source":"DrugCentral","target":"Sodium channel protein type 5 subunit alpha","protein":"Sodium channel protein type 5 subunit alpha"}],"modality":"Small Molecule","drugClass":"ajmaline","explanation":"Think of your heart as a pump that beats in a regular rhythm. Potassium channels help control how fast the heart beats. Ajmaline blocks these channels, which helps to slow down the heart rate and restore a normal rhythm.","oneSentence":"Ajmaline works by blocking potassium channels in the heart to help regulate heart rhythm.","technicalDetail":"Ajmaline acts as a selective blocker of the potassium voltage-gated channel subfamily A member 5 (hKv1.5), which is involved in the repolarization phase of the cardiac action potential."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/100","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AJMALINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AJMALINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:31:12.612836","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T10:51:32.456882+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"quinidine","drugSlug":"quinidine","fdaApproval":"1950-07-12","genericCount":35,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"procainamide","drugSlug":"procainamide","fdaApproval":"1950-06-02","genericCount":26,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"disopyramide","drugSlug":"disopyramide","fdaApproval":"1977-09-01","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"ajmaline","indications":{"approved":[{"name":"Cardiac arrhythmia","source":"DrugCentral","snomedId":698247007,"regulator":"FDA"},{"name":"Supraventricular arrhythmia","source":"DrugCentral","snomedId":72654001,"regulator":"FDA"},{"name":"Ventricular arrhythmia","source":"DrugCentral","snomedId":44103008,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"quinidine","brandName":"quinidine","genericName":"quinidine","approvalYear":"1950","relationship":"same-class"},{"drugId":"procainamide","brandName":"procainamide","genericName":"procainamide","approvalYear":"1950","relationship":"same-class"},{"drugId":"disopyramide","brandName":"disopyramide","genericName":"disopyramide","approvalYear":"1977","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06376552","phase":"","title":"Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2018-12-19","conditions":["Brugada Syndrome"],"enrollment":200,"completionDate":"2022-06-06"},{"nctId":"NCT03992677","phase":"","title":"Feasibility of Improving Risk Stratification in Brugada Syndrome","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2017-12-01","conditions":["Brugada Syndrome","Cardiac Arrest","Athletes Heart","Atrial Fibrillation","Ventricular Ectopic Beat"],"enrollment":45,"completionDate":"2022-08-01"},{"nctId":"NCT04580992","phase":"","title":"Defining the Electrocardiographic Effect of Propofol on the Ajmaline Provocation Drug Challenge: A Prospective Trial","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2020-11-16","conditions":["Brugada Syndrome","Channelopathies","Ventricular Fibrillation","Cardiac Death"],"enrollment":25,"completionDate":"2022-10-31"},{"nctId":"NCT03524079","phase":"","title":"Right Ventricle Morphology and Hemodynamics in BrS","status":"COMPLETED","sponsor":"IRCCS Policlinico S. Donato","startDate":"2018-04-19","conditions":["Brugada Syndrome"],"enrollment":60,"completionDate":"2019-11-09"},{"nctId":"NCT02933437","phase":"PHASE2","title":"The Response To Ajmaline Provocation in Healthy Subjects","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2017-10-22","conditions":["Brugada Syndrome","Sudden Death"],"enrollment":100,"completionDate":"2019-12"},{"nctId":"NCT02052765","phase":"NA","title":"AnalyST & Brugada Syndrome - Feasibility Study","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2011-02","conditions":["Brugada Syndrome"],"enrollment":16,"completionDate":"2011-05"},{"nctId":"NCT03491475","phase":"","title":"Echocardiography During Ajmaline Test","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2018-03-26","conditions":["Brugada Syndrome"],"enrollment":100,"completionDate":"2019-05-31"},{"nctId":"NCT02641431","phase":"NA","title":"Epicardial Ablation in Brugada Syndrome","status":"COMPLETED","sponsor":"IRCCS Policlinico S. Donato","startDate":"2015-11-16","conditions":["Brugada Syndrome"],"enrollment":135,"completionDate":"2016-12-30"},{"nctId":"NCT00702117","phase":"PHASE4","title":"Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2008-06","conditions":["Atrial Fibrillation","Tachycardia, Ventricular","Brugada Syndrome"],"enrollment":123,"completionDate":"2010-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000166953","NDDF":"003818","UNII":"1PON08459R","CHEBI":"CHEBI:28462","RXNORM":"423","UMLSCUI":"C0001888","ChEMBL_ID":"CHEMBL2105617","KEGG_DRUG":"D00199","DRUGBANK_ID":"DB01426","PDB_CHEM_ID":" AJM","PUBCHEM_CID":"6100671","SNOMEDCT_US":"1156230005","SECONDARY_CAS_RN":"4410-48-4","MESH_DESCRIPTOR_UI":"D000404"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"7.3 hours","clearance":"9.8 mL/min/kg","fractionUnbound":"0.24%","volumeOfDistribution":"4.0 L/kg"},"publicationCount":1045,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C01BA05","allCodes":["C01BA05"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ajmaline, a small molecule drug, targets the potassium voltage-gated channel subfamily A member 5 to treat cardiac arrhythmias, including supraventricular and ventricular arrhythmias. Its mechanism of action involves blocking potassium channels, which helps to regulate heart rhythm. The commercial status of ajmaline is unclear, and it may be patented or have generic manufacturers. Key safety considerations include its potential to cause cardiac side effects. Ajmaline has a half-life of 7.3 hours.","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":4,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T10:51:32.456882+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}